Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 16, 2026
Why Is AST SpaceMobile (ASTS) Stock Down -9.67% Today?

Why Is AST SpaceMobile (ASTS) Stock Down -9.67% Today?

Key Takeaways

  • AST SpaceMobile shares plunged 9.67% in Thursday's regular session, extending a steep after-hours selloff triggered by a $1 billion convertible notes offering.
  • The primary catalyst is the company's announcement of a $1.0 billion private offering of convertible senior notes due 2034, reigniting investor fears of share dilution.
  • A secondary headwind emerged as the company disclosed it now expects to deploy roughly 45 BlueBird satellites in early 2027, a delay from its prior late-2026 commercial service timeline.
  • Broader space-sector weakness and uncertainty around launch-provider capacity — particularly after Blue Origin's New Glenn setback — compounded the negative sentiment.
  • Traders are now watching for final pricing of the notes, the upcoming August launch of BlueBirds 11–13, and any clarity on potential acquisition targets hinted at in the offering documents.

Opening Summary

Shares of ASTS, AST SpaceMobile — the company building a space-based cellular broadband network designed to connect directly to standard smartphones — tumbled 9.67% on Thursday, extending a rout that began in Wednesday's after-hours session. The stock traded at $59.90 as of midday, down sharply from Wednesday's official close of $66.31. The selloff was triggered by the company's disclosure after the closing bell on July 15 that it intends to raise $1.0 billion through a private offering of convertible senior notes due 2034, with an additional $150 million option for initial purchasers. Investors immediately focused on the potential dilution to existing shareholders and the implications of yet another large capital raise for the pre-revenue satellite operator.

$1 Billion Convertible Notes Offering Reignites Dilution Fears

The dominant force behind the selloff is AST SpaceMobile's announcement of a $1.0 billion convertible senior notes offering. The notes carry a 1.625% annual coupon and an initial conversion price of approximately $79.57 per share, representing a 20% premium over the July 15 closing price. The company also entered into capped call transactions with an initial cap price of $149.20 per share, a mechanism designed to reduce potential dilution if the notes are eventually converted into equity.

Despite these protective features, the market reaction was overwhelmingly negative. This marks the company's fifth convertible debt issuance since January 2025 and its second $1 billion raise in just five months. The cumulative gross principal from convertible offerings now stands at approximately $4.26 billion. For a company with annual revenue of roughly $70.9 million and negative earnings per share, the repeated reliance on convertible debt has made dilution a persistent concern. The stock's after-hours drop of roughly 13% on Wednesday carried directly into Thursday's regular trading, with ASTS breaching multiple technical support levels in the process.

Launch Timeline Delay Adds to Investor Anxiety

Compounding the financing concerns, AST SpaceMobile's regulatory filing revealed that the company now expects its launch campaign to target approximately 45 BlueBird satellites in early 2027, a shift from its previous late-2026 commercial service target. The delay is tied in part to reduced launch capacity following Blue Origin's New Glenn rocket explosion, which sidelined one of the key launch vehicles AST had been counting on for its deployment schedule.

The company recently used SpaceX's Falcon 9 to successfully launch BlueBirds 8, 9, and 10 in June, and BlueBirds 11, 12, and 13 are scheduled for an August launch. However, reaching the 45-to-60 satellite threshold needed for continuous coverage in key markets such as the United States, Europe, and Japan remains a capital-intensive, multi-launch undertaking. The timeline shift underscores the execution risk inherent in AST's business model and adds pressure to an already uncertain path to commercial revenue generation.

Acquisition Speculation and Strategic Uncertainty

Adding another layer of complexity, AST SpaceMobile stated that a portion of the net proceeds may be used to pursue "partnerships and/or acquisitions to further vertically integrate its business and mitigate risks associated with third-party launch providers." While the company emphasized it has no current agreements in place, the language was enough to spark immediate speculation about potential acquisition targets, including United Launch Alliance, Firefly Aerospace, Relativity Space, and Stoke Space.

Some analysts interpreted the move as a strategic pivot toward a Rocket Lab-style vertical integration model, where the company would own both satellite manufacturing and launch capabilities. However, the market appears skeptical. Without a clearly identified target or a defined path to near-term launch capacity improvement, the acquisition language introduced more uncertainty than clarity, further weighing on the stock.

Market Context and Trading Activity

The selloff in ASTS is occurring against a backdrop of broader weakness in space-sector equities. The stock had already fallen 3.65% during Wednesday's regular session before the convertible notes announcement, and it is down roughly 27% over the past three months. Trading volume surged well above average as the after-hours breakdown carried into Thursday's session, reflecting intense institutional and retail repositioning.

From a technical standpoint, ASTS has broken below all major moving averages on the daily chart, with the 20-day, 50-day, and 200-day exponential moving averages now sitting well above the current price. The daily Relative Strength Index has fallen into the mid-30s, approaching oversold territory but not yet signaling a reversal. The stock is testing support near the $58–$60 range, with the psychologically important $50 level representing the next major downside marker if selling pressure persists.

Trending AI Robots

In volatile market environments like the one currently affecting ASTS, traders often turn to automated strategies to navigate rapid price swings with discipline. Tickeron's Trending AI Robots page features a curated selection of AI-powered trading bots that have demonstrated strong performance under current market conditions. With hundreds of bots covering thousands of tickers across multiple strategies, timeframes, and performance metrics, only the top performers are showcased in this dynamic section. Whether you are looking for short-term momentum plays or longer-duration trend-following approaches, exploring the Trending AI Robots can help you identify data-driven strategies aligned with today's market dynamics.

What Comes Next for ASTS

The immediate focus for ASTS will be the final pricing and settlement of the convertible notes offering, expected on July 20. Favorable terms — a higher conversion premium and lower coupon — could help stabilize sentiment, while less attractive pricing may extend the selloff. Beyond the financing, the August launch of BlueBirds 11, 12, and 13 from Cape Canaveral represents the next major operational milestone. Successful deployment and activation of these satellites would demonstrate continued technical progress toward the commercial service goal.

On the regulatory front, AST SpaceMobile has already secured significant approvals, including FCC authorization for a 248-satellite constellation and spectrum access through partners such as T and VZ. The company is also in advanced discussions with Japan's Rakuten Group regarding a potential subsidy of up to 148 billion yen (approximately $1 billion) for the J-LEO satellite project, though that funding is not yet committed. Analysts remain divided, with Piper Sandler initiating coverage with an Overweight rating and a $100 price target, while the broader consensus reflects a Hold rating with an average target near $81.47. The wide dispersion in analyst views underscores the high-risk, high-reward nature of the stock as it navigates the critical transition from technology demonstration to commercial service.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ASTS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for ASTS turns positive, indicating new upward trend

ASTS saw its Momentum Indicator move above the 0 level on July 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ASTS's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ASTS just turned positive on July 31, 2026. Looking at past instances where ASTS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ASTS advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

ASTS moved below its 50-day moving average on July 01, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for ASTS moved below the 200-day moving average on July 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ASTS broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ASTS entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ASTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.331) is normal, around the industry mean (7.453). P/E Ratio (0.000) is within average values for comparable stocks, (69.126). ASTS's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.191). ASTS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). ASTS's P/S Ratio (232.558) is very high in comparison to the industry average of (14.864).

Notable companies

The most notable companies in this group are Cisco Systems (NASDAQ:CSCO), Hewlett Packard Enterprise Company (NYSE:HPE), Lumentum Holdings (NASDAQ:LITE), Ciena Corp (NYSE:CIEN), Nokia Corp (NYSE:NOK), Ericsson (NASDAQ:ERIC).

Industry description

The Telecommunications Equipment industry produces voice and data communications equipment, which includes fiber optic delivery products, digital signal processors, high-speed voice, data and video delivery. Additionally, satellite systems, global positioning systems, wireless data systems, personal communications equipment, telephone handsets and payload equipment for satellites also fall into this category. Apple Inc., QUALCOMM Incorporated and Nokia are major global players in this segment.

Market Cap

The average market capitalization across the Telecommunications Equipment Industry is 22.11B. The market cap for tickers in the group ranges from 1.59K to 478.61B. CSCO holds the highest valuation in this group at 478.61B. The lowest valued company is ABILF at 1.59K.

High and low price notable news

The average weekly price growth across all stocks in the Telecommunications Equipment Industry was 12%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 29%. CLRO experienced the highest price growth at 127%, while INSG experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the Telecommunications Equipment Industry was -13%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 53
Price Growth Rating: 47
SMR Rating: 74
Profit Risk Rating: 75
Seasonality Score: -7 (-100 ... +100)
View a ticker or compare two or three
ASTS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a blank check company, which has formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization

Industry TelecommunicationsEquipment

Profile
Details
Industry
N/A
Address
2901 Enterprise Lane
Phone
+1 432 276-3966
Employees
1126
Web
https://www.ast-science.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.